Your browser doesn't support javascript.
Prediction Value of KREBS Von Den Lungen-6 (KL-6) Biomarker in COVID-19 Patients: A Systematic Review and Meta-Analysis.
Matuszewski, Michal; Szarpak, Lukasz; Rafique, Zubaid; Peacock, Frank W; Pruc, Michal; Szwed, Piotr; Chirico, Francesco; Navolokina, Alla; Ladny, Jerzy R; Denegri, Andrea.
  • Matuszewski M; Department of Anaesthesiology and Intensive Therapy at the Central Clinical Hospital of the Ministry of Interior and Administration, 02-507 Warsaw, Poland.
  • Szarpak L; Henry JN Taub Department of Emergency Medicine, Baylor College of Medicine, Houston, TX 77030, USA.
  • Rafique Z; Institute of Outcomes Research, Maria Sklodowska-Curie Medical Academy, 00-136 Warsaw, Poland.
  • Peacock FW; Henry JN Taub Department of Emergency Medicine, Baylor College of Medicine, Houston, TX 77030, USA.
  • Pruc M; Henry JN Taub Department of Emergency Medicine, Baylor College of Medicine, Houston, TX 77030, USA.
  • Szwed P; Research Unit, Polish Society of Disaster Medicine, 05-806 Warsaw, Poland.
  • Chirico F; 1st Chair and Department of Cardiology, Medical University of Warsaw, 02-097 Warsaw, Poland.
  • Navolokina A; Post-Graduate School of Occupational Health, Università Cattolica del Sacro Cuore, 00168 Rome, Italy.
  • Ladny JR; Health Service Department, Italian State Police, Ministry of the Interior, 20121 Milan, Italy.
  • Denegri A; Department of Public Health and Social Medicine, International European University, 03187 Kyiv, Ukraine.
J Clin Med ; 11(21)2022 Nov 07.
Article in English | MEDLINE | ID: covidwho-2110146
ABSTRACT
The SARS-CoV-2 (COVID-19) pandemic is a major issue that necessitates the use of cutting-edge disease prediction models. The aim of the study was to assess the existing evidence regarding association between Krebs von den Lungen-6 levels and COVID-19 severity. A literature search was performed on Web of Science, PubMed, Scopus and Cochrane Central Register of Controlled Trials databases from 1 January 2020 up to 2 August 2022. The electronic database search was supplemented by searching Google Scholar. In addition, reference lists of relative articles were also reviewed. KL-6 levels among COVID-19 positive vs. negative patients varied and amounted to 443.37 ± 249.33 vs. 205.73 ± 86.8 U/mL (MD = 275.33; 95%CI 144.57 to 406.09; p < 0.001). The KL-6 level was 402.82 ± 261.16 U/mL in the severe group and was statistically significantly higher than in the non-severe group (297.38 ± 90.46 U/mL; MD = 192.45; 95%CI 118.19 to 266.72; p < 0.001). The KL-6 level in the mild group was 272.28 ± 95.42 U/mL, compared to 268.04 ± 55.04 U/mL in the moderate COVID-19 group (MD = -12.58; 95%CI -21.59 to -3.57; p = 0.006). Our meta-analysis indicates a significant association between increased KL-6 levels and SARS-CoV-2 infection. Moreover, KL-6 levels are significantly higher in patients with a more severe course of COVID-19, indicating that KL-6 may be a useful predictor to identify patients at risk for severe COVID-19.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Prognostic study / Reviews / Systematic review/Meta Analysis Language: English Year: 2022 Document Type: Article Affiliation country: Jcm11216600

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Prognostic study / Reviews / Systematic review/Meta Analysis Language: English Year: 2022 Document Type: Article Affiliation country: Jcm11216600